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Abstract
Background: Prolyl Endopeptidase (PEP, EC 3.4.21.26), a cytosolic endopeptidase, hydrolyses
peptide bonds on the carboxyl side of proline residue in proteins with a relatively small molecular
weight. It has been shown that altered PEP activity is associated with various psychological diseases
such as schizophrenia, mania and depression. Autistic Spectrum Disorders (ASD) are
neuropsychiatric and behavioural syndromes affecting social behaviours and communication
development. They are classified as developmental disorders. The aim of this study was to examine
the hypothesis that PEP activity is also associated with ASDs.
Methods: Fluorometric assay was used to measure PEP activity in EDTA plasma in children with
ASD (n = 18) aged 4–12 years (mean ± SD: 7.9 ± 2.5). These results were then compared to PEP
activity in a control group of non-ASD children (n = 15) aged 2–10 years (mean ± SD: 6.4 ± 2.2).
Results: An alteration in PEP activity was found in the children with ASD compared to the control
group. There was much greater variation of PEP activity in the group of ASD children when
compared to the controls (SD= 39.9 and SD 9.6, respectively). This variation was significant (p <
0.0005), although the mean level of PEP activity in the group of ASD children was slightly higher
than in the control group (124.4 and 134.1, respectively).
Conclusion: Our preliminary finding suggests a role for PEP enzyme in the pathophysiology of
autism but further research should be conducted to establish its role in the aetiology of psychiatric
and neurological disorders, including autism and related spectrum disorders.
Background
Prolyl Endopeptidase (PEP, EC 3.4.21.26) is a cytosolic
endopeptidase. PEP cleaves peptide bonds on the car-
boxyl side of proline residues in low molecular weight
proteins containing the recognition sequence X-Pro-Y,
where X is a peptide or protected amino acid and Y is an
amide, a peptide, an amino acid, an aromatic amine or an
alcohol [1]. PEP can only hydrolyse small peptides and is
thought to be involved in the metabolism of hormones/
neuropeptides. However, PEP also degrades many active
hormones/neuropeptides, e.g. oxytocin, arginine vaso-
pressin (AVP), substance P, neurotensin, luteinizing
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releasing hormone (TRH) [2]. These low molecular
weight proteins, particularly oxytocin, AVP, TRH, neuro-
tensin, and substance P, profoundly affect social behav-
iour, emotions, stress level, responsivity, reward-seeking
and positive reinforcement behaviour [3]. Altered PEP
activity has been observed in psychiatric disorders such as
depression, mania and schizophrenia [4].
Autistic Spectrum Disorders (ASD) are neuropsychiatric
and behavioural syndromes affecting social and commu-
nicative development. They were classified as develop-
mental disorders in DSM-IV (American Psychiatric
Association 1994) [5]. Severe communication deficits and
social and behavioural abnormalities often appear during
the first three years of life but the diagnosis is often made
later, due to a lack of resources. The aetiology of ASD is
not yet known. Symptoms of ASDs are related to the
abnormal functioning of certain centres within the brain:
in particular the cerebellum, brain stem and limbic region
[6]. ASDs are also associated with several specific dysfunc-
tions including fragile X syndrome [7], a cascade of com-
plex gene-environment interactions [8,9],
hyperserotoninemia, [10,11], increased levels of opioid
[12,13] and high levels of arginine-vasopressin (AVP)
[our unpublished observation]. Low plasma levels of the
neuropeptide hormone oxytocin have also been found in
a group of children with ASD when compared to the nor-
mal age-matched controls [14].
Altered levels of the neuropeptide hormones oxytocin,
arginine vasopressin and other related hormones/pep-
tides may be a result of proteolytic enzyme activity such as
PEP, which is involved in the formation and degradation
of various neuropeptides. Our hypothesis is that altered
activity of proteolytic enzymes, such as PEP, in children
with ASD (children <12 years) might lead to the degrada-
tion of some specific neuropeptide hormones, affecting





obtained from Bachem in Bubendorf, Switzerland. Dithi-
othereitol, ethylenediamineteraacetic acid disodium salt
dihydrate (EDTA), benzamidinium chloride, p-chlo-
romercuribenzoate (PCMB) and pepstatin, sodium azide,
dithiothereitol (DTT) were obtained from Sigma in St.
Louis, Missouri USA. Acetic acid and 1,4-dioxan were
obtained from Merk in Darmstadt, Germany. A Perkin
Elmer Fluorimeter LS 50B was used to determine the
release of 7-amino-4-methylcoumarine at excitation and
emission wavelengths of 370 nM and 440 nM.
Subjects
Eighteen ASD and a control group of 15 non-ASD chil-
dren participated in this study. The children with ASD
were selected from children attending rehabilitation cen-
tres in Sweden. The original diagnosis of ASD was made
jointly by a psychiatrist and psychologist who made the
diagnosis in accordance with DSM IV (APA, 2000) and the
International Classification of Diseases (ICD) (WHO,
1993). Their diagnosis was then independently confirmed
by the specialist in autism spectrum disorders at Lund uni-
versity hospital. As a routine measure, these children
undergo health checks including a dental examination.
This requires the children to be anaesthetised, since many
children with ASD are unable to understand what is
required of them and incapable of cooperating when a
dental examination is carried out. During our research
period 18 ASD children underwent this examination.
Wechsler Intelligence Scale for Children (WISC) was used
to estimate the children's functional abilities. The ASD
group consisted of 14 boys and four girls ranging from 4
to 12 years (mean 7.9 years; SD, 2.5). Information about
additional dysfunction and medication was not available.
Paediatricians at the children's hospital selected the chil-
dren in the control group when they came to the hospital
to be treated for various physical conditions. None of the
children in the control group had any mental disabilities.
The control group (non-ASD) consisted of nine boys and
seven girls ranging from 2–10 years (mean 6.4 years; SD,
2.2), (Table 1).
The Ethics Committee at the Faculty of Medicine, Lund
University, approved this study (LU-70-00).
Sample collection
Venous blood from ASD children was collected under
general anaesthesia when they were undergoing another
medical treatment. This was done in the presence of a
child psychiatrist with special training in the field of child-
hood psychosis. Venous blood from a control group of
non-ASD children was collected in evacuated 4 mL EDTA
tubes, containing 0.084 ml of 0.34 M K3-EDTA solution.
These tubes (Vacutainer System) were obtained from Bec-
ton-Dickinson Inc., Plymouth, UK. Plasma from EDTA-
containing blood was produced immediately after collec-
tion by centrifugation at 1300 g for 10 min at 4°C. 30 µL
of cocktail inhibitors per 1 mL plasma was then added to
the produced plasma sample. The inhibitor cocktail stock
solution used was Tris 2.0 M, Na-EDTA 0.9 M, Benzami-
din 0.2 M, E-64,10 µM and Pepstatin 48 µM. The PEP
activity of the samples was analysed immediately after the
production of plasma. The remaining samples were stored
for further investigation at -70°C.Page 2 of 6
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The method used to assay the PEP using the hydrolysis of
the fluorogenic substrate (Z-Gly-Pro-4-methylcoumari-
nyl-7-amide) has previously been described by Momeni
et. al. [15]. This study showed that different factors such as
temperature, freeze-thawing cycles, substrate concentra-
tion, the organic solvent used to dissolve the substrate and
the time of incubation of enzyme-substrate mixture influ-
enced the final fluorescence intensity. 20 µL of plasma
was incubated with 200 µL of buffer (100 mM phosphate
buffer, pH 7.5, with 1 mM EDTA, 1 mM DTT and 1 mM
sodium azide) for 10 min at 37°C to reach thermal equi-
librium. 5 µL of the substrate solution containing 18.4
mM Z-Gly-Pro-4-methylcoumarinyl-7-amide was then
added and the mixture incubated at 37°C for 120 min.
The reaction was then terminated by the addition of 1000
µL of 1.5 M acetic acid and the release of 7-amino-4-meth-
ylcoumarin measured in a fluorimeter (λex: 370 nm; λem:
440 nm; slit width: 2.5). The substrate solution was pre-
pared by dissolving Z-Gly-Pro-4-methylcoumarinyl-7-
amide in 100% 1,4-dioxane and then diluting to 50% (v/
v) with incubation buffer. All measurements were carried
out in triplicate.
The flourometric assay originally used by Goossens et al
[16] was incapable of detecting low PEP activity in CSF. By
further developing the procedure of previous work [15] it
was possible to achieve a 400% improvement in assay
sensitivity and detect PEP in CSF [15]. Triple assays of
each sample were carried out. Any variation in results was
insignificant, which confirmed the reliability of the proce-
dure. The average for each of the three results was used for
the calculations.
Statistical analysis
The figure for the fluorescence intensity and the children's
age (Mean +/- statistical deviation) in the two groups were
calculated and plotted on a graph. Mann-Whitney U-test
was used to test the difference of mean for PEP activity.
Levene's test for equality of variances was used for the
comparison between the ASD and non-ASD groups of
children. SPSS version 11.2 (Norusis, M.J./SPPS Inc.,
2004) was used.
Results
Basal plasma PEP activities in the control group (n = 15)
were between 105.4 and 144.0 fluorescence intensity
units (mean 124.4, median 125.6). The activity of PEP in
the 18 ASD children ranged from 48.1 to 201.9 fluores-
cence intensity units (mean 134.1, median 147.6) (Table
1).
The mean level of PEP activity in children with ASD was
only slightly higher than that in the controls but the vari-
ation of PEP activity was much larger in ASD children
than in the controls (SD = 39.9 and 9.6, respectively). The
difference was significant (Levene's test for equality of var-
iances yielded F (17,14) = 16.4, p < 0.0005) (Fig. 1). The
ASD children were 4–12 years old (mean ± SD: 7.9 ± 2.5),
the control group were 2–10 years old (mean ± SD: 6.4 ±
2.2). The variation of enzyme activity is shown in Fig. 2.
Table 1: PEP activity (fluorescence intensity unit) of EDTA plasma and age in control (n = 15) and ASD groups (n= 18).




Std. Deviation 9.6 2.2
Minimum 105.4 2
Maximum 144.0 10





Std. Deviation 39.9 2.5
Minimum 48.1 4
Maximum 201 12
Percentiles 25 109.3 6
50 147.6 8
75 160.2 10Page 3 of 6
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Proline endopeptidase, a cytosolic enzyme isolated from
human tissues, cleaves different low-molecular-weight
neuropeptide hormones such as oxytocin, AVP, TRH, neu-
rotensin, bradykinin and substance P. The neuropeptide
hormones, which contain a proline in the carboxyl side of
their sequences, act as a substrate for PEP. It has been
reported that PEP activity is altered in individuals with
depression, mania and schizophrenia [4]. High PEP
serum activity has also been reported in patients with
PTSD (post-traumatic stress disorder) [17]. The result of
this study showed a significantly higher variance of the
PEP activity in the group of ASD children. There may be
various explanations for this finding, including the heter-
ogeneity of individuals in the ASD group and the effects of
pharmaceuticals [4]. The general anaesthesia (GA) may
also have an impact on PEP activity. The precise effect of
GA on enzyme activity is currently unknown. This ques-
tion will be addressed in the next study.
This alteration of PEP activity may support our hypothesis
that PEP might be involved in the aetiology of ASD. How-
ever, our working hypothesis is that ASD can be caused or
influenced by external events in early childhood, possibly
as result of a genetic predisposition. As a result there may
be an inappropriate release of the cytosolic proteolytic
enzyme PEP into the circulating blood stream and the cer-
ebrospinal fluid (CSF). PEP cleaves different neuropep-
tides or their precursor molecules leading to an alteration
of the concentration of neuropeptides and this may have
a negative effect upon proper brain function.
The main deficits of children with ASD include early diffi-
culties with social contact, such as eye contact and social
smile [18,19], attention [20], affects [21,22], reciprocity
[18,23], turn-taking, timing and answering parents' sig-
nals [21]. Many different problems can arise with respect
to co-ordination and motor planning [18,24], body tonus
deficits [19], and problems with mobility. Children with
ASD have a tendency to ignore other people or may even
prefer to be alone [19]. They also have difficulties in
signalling for attention and they communicate without
meeting the gaze of another person [18]. This could be
explained by the effects PEP might have on the neuropep-
tide hormones when cleaving them and interfering with
their proper functions in the processes of early brain
development.
In three children with ASD, the PEP activity was lower
than the mean activity of the control group. Twelve ASD
children had higher PEP activity than average and the
remaining three had PEP activity equal to that of the con-
trol group. This variation may be related to different psy-
chiatric disorder from which the patients were suffering,
such as depression or mania. There was no significant
Variation of PEP activity in EDTA plasma in the control group (n = 14), interqu r le ra ge (115.8–130.7), and in he ASD group (n = 18), interqu rtil  range ( 09 3–160.2)Fig re 1
Variation of PEP activity in EDTA plasma in the control group 
(n = 14), interquartile range (115.8–130.7), and in the ASD 
group (n = 18), interquartile range (109.3–160.2).
Variation of plasma PEP activity in the children with ASD (n = 18) nd in a non-ASD con rol group (n = 14) associated to ageFigure 2
Variation of plasma PEP activity in the children with ASD (n = 
18) and in a non-ASD control group (n = 14) associated to 
age.Page 4 of 6
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neither was there any great variation but in the ASD group
there was a significant variation, randomly distributed
between the sexes.
We did not measure PEP activity in the cerebrospinal fluid
(CSF) of the ASD children. It might differ from plasma
PEP activity. In a previously published article [15] PEP
activities was measured in both CSF and EDTA plasma in
patients suffering from another neurological disease in
order to investigate whether PEP activity differs in these
two substances from the same patient. The result showed
a variation in PEP activity in plasma compared to CSF.
This variation might be caused by a dysfunction in the
blood brain barrier (BBB) that might allow substances
such as PEP to pass through the barrier and continue its
activity in the circulating blood. BBB dysfunction might
also be implicated in the variation of the EDTA plasma
PEP activity in the children with ASD.
Due to the pioneering nature of this research it is difficult
to relate the finding of this study to other biomedical
research on ASD. Research is also limited regarding PEP
activity associated with other psychiatric disorders.
Altered prolyl endopeptidase activity in plasma has been
associated with major depressed patients (low levels) and
with manic and schizophrenic patients (high levels) [4].
This preliminary finding may indicate an association
between altered PEP activity and neuro-psychiatric disor-
ders such as ASDs.
Conclusion
Our preliminary finding suggests a role for PEP enzyme in
the pathophysiology of autism but further research
should be conducted to establish its role in the aetiology
of psychiatric and neurological disorders, including
autism and related spectrum disorders.
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